Literature DB >> 11251334

Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations.

K E Knobe1, B O Villoutreix, L I Tengborn, P Petrini, R C Ljung.   

Abstract

The development of inhibitory antibodies against coagulation factor VIII (FVIII) in patients with mild haemophilia A is uncommon. We describe here two families in which three or two members have developed inhibitors, suggesting a familial predisposition. The mutations found, in the A2 (Arg593Cys) and C1 domains (Tyr2105Cys), have been reported to give rise to inhibitor development in single individuals in addition to the family cluster we describe, strongly suggesting that these amino acid substitutions give rise to a more immunogenic protein. The analysis of structural models of activated factor VIII revealed that Arg593 is solvent-exposed and involved in a network of electrostatic interactions while Tyr2105 is partially buried and has hydrophobic interactions essentially with Ile2144. All these residues are strictly conserved in the FVIII amino acid sequence from man, pig and mouse, suggesting, at least, that they have structural roles. We propose that the two mutations in these families could cause mild haemophilia A because they induce local conformational changes (and possible secretion or intermolecular interaction problems, e.g., with von Willebrand factor) compatible with immunogenicity and production of inhibitors against the infused wild-type FVIII. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11251334     DOI: 10.1159/000054143

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  4 in total

Review 1.  Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.

Authors:  Anna Chiara Giuffrida; Sabrina Genesini; Massimo Franchini; Marzia De Gironcoli; Giuseppe Aprili; Giorgio Gandini
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

2.  Severe non-traumatic bleeding, the answer is not in the blood.

Authors:  Marco Tana; Claudio Tana; Paolo Amerio; Gianfranco Vitullo; Paolo di Giosia; Concetta di Febbo; Giovanni Davì
Journal:  Intern Emerg Med       Date:  2015-02-26       Impact factor: 3.397

3.  In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.

Authors:  C L Kempton; J M Soucie; C H Miller; C Hooper; M A Escobar; A J Cohen; N S Key; A R Thompson; T C Abshire
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

4.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.